To reduce the toxic effects, related clinical problems and complications such as bleeding disorders associated with systemic anticoagulation, it has been hypothesized that by coating the surfaces of medical devices, such as stents, bypass grafts, extracorporeal circuits, guide wires and catheters, there will be a significant reduction in the requirement for systemic anticoagulation or, ideally, it will no longer be necessary. However, current coating processes, even covalent ones, still result in leaching followed by reduced functionality. Alternative anticoagulants and related antiplatelet agents have been used for improvement in terms of reduced restenosis, intimal hyperphasia and device failure. This review focuses on existing heparinization processes, their application in clinical devices and the updated list of alternatives to heparinization in order to obtain a broad overview, it then highlights, in particular, the future possibilities of using heparin and related moieties to tissue engineer scaffolds.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/17434440.3.2.245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refining Stroke Risk Assessment in Patients with Device-Detected Atrial Fibrillation.
J Clin Med
December 2024
Department of Cardiology, Esbjerg Hospital-University Hospital of Southern Denmark, Finsensgade 35, DK-6700 Esbjerg, Denmark.
Article Synopsis
- Clinical atrial fibrillation (AF) significantly raises the risk of stroke and systemic embolism, but treatment with oral anticoagulants can lower this risk while increasing the chance of major bleeding.
- Device-detected atrial fibrillation (DDAF) also poses a stroke risk, though lower than clinical AF, with studies showing that direct oral anticoagulation can reduce stroke risk for DDAF patients but similarly heightens bleeding risk.
- The challenge persists in determining how to effectively manage the balance between reducing thromboembolic risk and the increased risk of bleeding for DDAF patients, as well as identifying those who would benefit most from anticoagulant therapy.
Anticoagulation in venous thromboembolism in Behçet's syndrome: friend or foe?
RMD Open
December 2024
Respiratory Medicine Unit, Department of Cardiology Thoracic and Vascular Medicine, Pisa University Hospital, Pisa, Italy.
Upper Arm Deep Vein Thrombosis in a Patient with Active Lupus.
Eur J Case Rep Intern Med
December 2024
Radiology Department, Seychelles Hospital, Healthcare Agency, Victoria, Seychelles.
Unlabelled: Upper extremity deep vein thrombosis (UEDVT) is relatively rare, and much less as an initial presentation of systemic lupus erythematosus (SLE). Primary UEDVT should be considered in individuals with unilateral arm swelling where the brachial, axillary, and subclavian veins are frequently involved. SLE is a chronic autoimmune disease that predominantly affects women of childbearing age and of African descent.
View Article and Find Full Text PDFStatin therapy in ischemic stroke patients with atrial fibrillation: Efficacy and safety outcomes.
Eur Stroke J
January 2025
Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Introduction: The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.
View Article and Find Full Text PDFDevelopment and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older.
BMC Geriatr
January 2025
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd., Zhongzheng Dist., Taipei, 100025, Taiwan.
Background: To identify cardiovascular (CV) risk factors in Asian elderly aged 75 years and older and subsequently develop and validate a sex-specific five-year CV risk assessment tool for this population.
Methods: This study included 12,174 patients aged ≥ 75 years without a prior history of cardiovascular disease at a single hospital in Taiwan. Electronic health records were linked to the National Health Insurance Research Database and the National Death Registry to ensure comprehensive health information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!